CCL3 and breast cancer: Intriguingly, CathD has also been shown to selectively degrade macrophage inflammatory protein (MIP)-1α (CCL3), MIP-1β (CCL4), and SLC (CCL21) that, in turn, may affect the generation of the anti-tumoral immune response, the migration of human breast cancer cells, or both processes [92].